Journal of Medical Ethics 47 (12):16-16 (2021)

Authors
Douglas MacKay
University of North Carolina, Chapel Hill
Abstract
Hospital systems commonly face the challenge of determining just ways to allocate scarce drugs during national shortages. There is no standardised approach of how this should be instituted, but principles of distributive justice are commonly used so that patients who are most likely to benefit from the drug receive it. As a result, clinical indications, in which the evidence for the drug is assumed to be established, are often prioritised over research use. In this manuscript, we present a case of a phase II investigational trial of intravenous thiamine for delirium prevention in patients undergoing haematopoietic stem cell transplantation to emphasise several shortcomings in the overarching prioritisation of clinical over research uses of scarce drugs. Specifically, we present the following considerations: clinical use may not have stronger evidence than research use; a strong scientific rationale for research use may outweigh the claim for clinical indications in which there is weak evidence; treatment within the context of a clinical trial may be the standard of care; and research use may not only benefit patients receiving the treatment but also offers the prospect of improving future clinical care. In summary, we argue against allocation schemes that prohibit all research uses of scarce drugs and instead recommend that allocation schemes include a balanced approach that weighs risks and benefits of access to scarce drugs irrespective of the research versus clinical use designation. All data relevant to the study are included in the article.
Keywords No keywords specified (fix it)
Categories (categorize this paper)
DOI 10.1136/medethics-2020-106739
Options
Edit this record
Mark as duplicate
Export citation
Find it on Scholar
Request removal from index
Revision history

Download options

PhilArchive copy


Upload a copy of this paper     Check publisher's policy     Papers currently archived: 71,259
External links

Setup an account with your affiliations in order to access resources via your University's proxy server
Configure custom proxy (use this if your affiliation does not provide a proxy)
Through your library

References found in this work BETA

Payment for Research Participation: A Coercive Offer?A. Wertheimer & F. G. Miller - 2008 - Journal of Medical Ethics 34 (5):389-392.
The Tensions and Challenges of Unpredictable Drug Shortages.Annekathryn Goodman - 2012 - American Journal of Bioethics 12 (1):20 - 22.

View all 7 references / Add more references

Citations of this work BETA

No citations found.

Add more citations

Similar books and articles

What We Worry About When We Worry About the Ethics of Clinical Research.David Wendler - 2011 - Theoretical Medicine and Bioethics 32 (3):161-180.
Clinical Research: Up From 'Clinical Epidemiology'.Olli S. Miettinen, Lucas M. Bachmann & Johann Steurer - 2009 - Journal of Evaluation in Clinical Practice 15 (6):1208-1213.
What Clinical Pharmacology Means to Us.S. Malhotra & N. Shafiq - 2006 - Mens Sana Monographs 4 (1):184.
Why High Drug Pricing Is A Problem for Research Ethics.Spencer Phillips Hey - 2020 - Journal of Bioethical Inquiry 17 (1):29-35.
Community Equipoise and the Architecture of Clinical Research.Jason H. T. Karlawish & John Lantos - 1997 - Cambridge Quarterly of Healthcare Ethics 6 (4):385-.
Community Equipoise and the Architecture of Clinical Research.Jason H. T. Karlawish & John Lantos - 1997 - Cambridge Quarterly of Healthcare Ethics 6 (4):385-396.

Analytics

Added to PP index
2020-11-28

Total views
6 ( #1,137,225 of 2,518,488 )

Recent downloads (6 months)
1 ( #408,186 of 2,518,488 )

How can I increase my downloads?

Downloads

My notes